-
<![CDATA[FDA Grants Breakthrough Status to Zoldonrasib in Lung Cancer]]>
08 Jan 2026 19:49 GMT
… mutation in non-small cell lung cancer.
“The breakthrough therapy … cell lung cancer with KRAS G12D mutations.
Non-small cell lung cancer accounts … to 85% of all lung cancers, with more than 197 … of non-small cell lung cancer cases, underscoring the potential …
-
<![CDATA[Top 5 Lung Cancer Stories of 2025: Research, Treatments and Patient Journeys]]>
07 Jan 2026 21:12 GMT
… to help surgeons see lung tumors in real time … improve visualization of primary lung cancer, pulmonary lesions, cancer … in Lung Cancer
New and unconventional targets in lung cancer may … lung cancer” by Dr. Rafal Dziadziuszko, et al., FDA
“Novel Targets (KRAS …
-
Brazilian study shows liquid biopsies can expedite lung cancer care
07 Jan 2026 19:57 GMT
… of genetic alterations in lung cancer through liquid biopsies could … patients with non-small cell lung cancer (NSCLC) using a … in EGFR and a specific KRAS mutation (p.G12C) can … clinical decisions for patients with lung cancer. The study reinforces the …
-
<![CDATA[Zoldonrasib Earns FDA Breakthrough Therapy Designation in KRAS G12D+ NSCLC]]>
09 Jan 2026 22:41 GMT
… non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations who … among patients with different KRAS G12D-mutated solid tumors. … prior treatment with an investigational KRAS G12D inhibitor, pan- … -9805 in participants with KRAS G12D-mutant solid tumors. …
-
<![CDATA[Zoldonrasib Earns FDA Breakthrough Therapy Status in KRAS G12D-Mutant NSCLC]]>
09 Jan 2026 20:34 GMT
… need for patients with KRAS G12D cancers, which currently … with advanced solid tumors harboring KRAS G12D mutations, including NSCLC, … -9805 in participants with KRAS G12D–mutant solid tumors. … in patients with KRAS G12D non-small cell lung cancer (NSCLC) from …
-
<![CDATA[Zoldonrasib Nets Breakthrough Therapy Designation in KRAS G12D–Mutated NSCLC]]>
08 Jan 2026 21:49 GMT
… of adult patients with KRAS G12D-mutated locally advanced … inhibitor in patients with advanced KRAS G12D-mutated solid tumors. … in patients with KRAS G12D non-small cell lung cancer (NSCLC) from … RMC-9805 in participants with KRAS G12D-mutant solid tumors. …
-
<![CDATA[Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC]]>
08 Jan 2026 20:20 GMT
… –small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. … of all patients with lung cancer globally,” said Gregory Lubiniecki … harboring the highly prevalent KRAS mutation. With potential antineoplastic … with non-small cell lung cancer (MK-1084-007…
-
Revolution Medicines' Zoldonrasib Gets FDA Breakthrough Therapy Status For KRAS G12D-mutated NSCLC
08 Jan 2026 14:25 GMT
… adult patients with KRAS G12D-mutated non-small cell lung cancer (NSCLC) who … zoldonrasib in patients with advanced KRAS G12D solid tumors. Results demonstrated …
-
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
10 Jan 2026 17:36 GMT
… irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal … Metastatic Non-small Cell Lung Cancer (METalmark). https:… Metastatic Non-small Cell Lung Cancer (swalloWTail). https:… Metastatic Non-small Cell Lung Cancer (PolyDamas). https:…
-
<![CDATA[The OncFive: Top Oncology Articles for the Week of 1/4]]>
10 Jan 2026 16:56 GMT
… with KRAS G12D–mutated locally advanced or metastatic non–small cell lung cancer …
About
© 1995-2026